PolyPid Announces Completion of Enrollment in Phase 3 SHIELD I Trial of D-PLEX₁₀₀ for Prevention of Surgical Site Infections in Abdominal Surgery

Following Unblinded Interim Efficacy Analysis, Data Safety Monitoring Board Recently Recommended Concluding Study at 950 Patients, the Minimum Number of Patients Targeted Top-line Results Expected by End of Q3 2022; Potential NDA and MAA Submissions Targeted for H1 2023 PETACH TIKVA, Israel , May